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161 The ﬁrst results of antimicrobial susceptibility of isolates from
adult patients with cystic ﬁbrosis from the Province of Vojvodina,
Serbia
D. Skrbic1, A. Trudic1, D. Povazan1, T. Kurucin1, M. Djuric1. 1Institute for
Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia
Over the past last few decades, cystic ﬁbrosis (CF) has changed from a disease of
childhood into a disease of adults. When a chronic infection of the lungs occurs,
eradication of the pathogens is almost impossible. In the Institute for Pulmonary
Diseases of Vojvodina, we have started the treatment of adult patients with cystic
ﬁbrosis in the year of 2010.
The aim of the study is to examine the patterns of antimicrobial susceptibility of
the pathogens isolated from adult patients with cystic ﬁbosis due to a rational use
of antimicrobial therapy.
The results are shown for the ﬁrst six adult patients with cystic ﬁbrosis treated
in the Institute, 5 females and 1 male, at the average age of 24.8 years. The
following microorganisms were isolated from sputum samples: Pseudomonas aeru-
ginosa 15 (45.5%), Pseudomonas species 11 (33.3%), Escherichia coli 5 (15.2%),
Klebsiella pneumoniae 1 (3%), Staphylococcus aureus 1 (3%). The isolated micro-
organisms showed high susceptibility rates to piperacillin–tazobactam (85.7%)
meropenem (81.8%), imipenem (78.8%), cefepime (81.8%), ceftazidime (78.8%),
ceftriaxone (72.2%). Susceptibility to ciproﬂoxacin was 68.7%, and to gentamicin
59.4%. Besides high susceptibility rates to carbapenems, similarly high suscepti-
bility rates of the isolated microorganisms were registered to the third and fourth
generation of cephalosporins.
The goal of monitoring the resistance of pathogens isolated from the patients with
cystic ﬁbrosis and the rational use of antimicrobial therapy is to reduce the number
of microorganisms and to maintain the patients’ pulmonary function and decrease
an irreversible damage of the pulmonary parenchyma.
162 Bronchial artery embolization (BAE) in adults with cystic ﬁbrosis:
a single-centre case series
M. Marquette1, N. Shaida2, C. Cousins2, A. Winterbottom2, C. Johnson1,
N. Shaﬁ1, C. Haworth1, H. Barker1. 1Papworth Hospital NHS Foundation Trust,
The Adult Cystic Fibrosis Unit, Cambridge, United Kingdom; 2Addenbrooke’s
Hospital NHS Foundation Trust, Radiology, Cambridge, United Kingdom
Objectives: To investigate indications and outcomes for BAE in CF Patients.
Methods: Retrospective case series of 28 CF adults who underwent BAE 2002–
2013. Data regarding clinical outcomes were collected via notes review.
Results: Mean age 27, range 16−68. Mean FEV1 pre BAE 39% predicted. 30%
referred for massive haemoptysis (>240ml), 20% for moderate (<100ml) and 50%
recurrent small volume haemoptysis. BAE was performed using PVA particles
following CTPA. 100% had good radiological results. Recurrent haemoptysis
occurred in 1 patient after, 10% shortly after and 20% within 1 year, with no massive
bleeds post BAE. 60% had no serious complications. 20% had chest pain pre BAE
and 50% severe chest pain post procedure, with CRP rising. Fever was present
in 10% pre and 50% post BAE. Inﬂammatory complications were associated with
chest pain and high CRP pre BAE. 2 patients died soon after BAE, of whom 1 had
retrograde emboli to kidneys and spleen, and 1 an immediate severe inﬂammatory
response and sepsis. 2 patients who had severe pain, fever and CRP rise post BAE
both died of progressive ventilatory failure. Complications were correlated with
smaller particle size and greater volume of particles used.
Conclusion: BAE may produce excellent radiological results and prevent massive
bleeds, it may not stop all bleeding and may cause harm via pulmonary inﬂamma-
tion. This may be reduced by minimising inﬂammation pre-BAE.
BAE may be beneﬁcial in massive haemoptysis but for others risks may outweigh
beneﬁts. Complications may occur when smaller particles are used or more exten-
sive BAE performed. It may be prudent to limit BAE to smaller areas using larger
particles.
163 TIVAD infection and TIVAD related cardiac problems in
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Introduction: Treatment with immunosuppressive medication increases the risk of
infection in transplanted CF patients. There are no recommendations with regards
to the removal of a TIVAD after lung transplantation.
Objective: To investigate the prevalence of bloodstream infections and cardiac
problems in CF patients with and without TIVAD.
Methods: Retrospective data from the CF patient cohort (n = 86, 50 female)
transplanted at the University Hospital Leuven (1992–2013): results of bloodstream
cultures (routine culture or for clinical indication) and trans esophageal echocardiog-
raphy comparing patients with and without TIVAD (mean post-transplant follow-up
77 (1–277) months).
Results: 49/86 (29 female) patients had a TIVAD at the time of transplantation. 11
TIVADs were removed after transplantation (5 due to infection, 6 due to technical
failure). Positive bloodstream cultures were found in 8 patients (8 positive cultures)
without TIVAD and in 20 patients (39 positive cultures) with TIVAD (p = 0.03,
Fischer exact test). 5 patients with TIVAD developed severe insufﬁciency of the
mitral valve and in 3 of these patients mitral valve replacement was needed while
no cardiac abnormalities were found in the the transplanted CF patients without
TIVAD (p = 0.08, Fischer exact test).
Discussion: A higher rate of positive bloodstream culture and mitral valve insufﬁ-
ciency were found after lung transplantation in CF patients with a TIVAD. Removal
of TIVAD seems warranted in CF patients after lung transplantation.
164 Incidence, management and outcomes following spontaneous
pneumothorax in adult patients with CF attending a Regional
Centre
C. Etherington1, H. Coleman1, P. Whitaker1, I. Clifton1, D. Peckham1. 1St.
James’s University Hospital, Regional Adult Cystic Fibrosis Centre, Leeds, United
Kingdom
Objectives: Spontaneous pneumothorax (PTX) is a well recognised complication
of CF. Our aim was to determine the incidence, success of different modalities of
treatment, impact on disease severity and outcomes.
Methods: Data were retrieved retrospectively from electronic patient records for
patients with 1 PTX between 2006 and 2013.
Results: 23 patients [median (range) age at ﬁrst episode 26.2 (15.9–45.9) yrs,
FEV1 27 (15−47) %predicted and BMI 18.6 (14–27.1) kg/m
2] had 36 episodes of
PTX. Incidence 0.6−1.8/100 patients/year. Initial management conservative (n = 2)
and chest drain (n = 21). 10 (48%) resolved with chest drain, 11 (52%) required
further management; medical talc pleurodesis (n = 2) and surgical VATS and talc
pleurodesis (n = 9) after 8 (3−14) days. 8 patients (35%) had a further 13 episodes
of PTX after 4.4 (0.5–55.4) months. Median FEV1 decreased from 44 (25−59) to
32 (20−47) % predicted, p = 0.048 in 2 yrs pre PTX. Patients required signiﬁcantly
more days of intravenous antibiotic treatment post vs.pre [98 (0–297) vs. 48 (0–
206) days, p< 0.01 and had a signiﬁcantly higher CRP level [114 (8.5–378) vs.
45 (5–245), p = 0.17]. 14 patients (61%) required LTOT post compared to 5 (22%)
pre PTX, p< 0.01. 5 patients had been referred for lung transplantation pre PTX; 10
patients (43%) required referral post PTX after 8.0 (0.9–80.80) months. 7 patients
(30%) have died (57% at 1 year, 14% at 2 years and 29% at 4 years); median
survival 8.3 (1.5−38) months post ﬁrst PTX.
Conclusion: Spontaneous PTX is a poor prognostic factor in CF associated with a
high risk of recurrence, increased treatment burden, decline in clinical status and
poor survival rates.
